The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Fc‐fusion proteins: new developments and future perspectives
Open accessAbstract
Since the first description in 1989 of CD4-Fc-fusion antagonists that inhibit human immune deficiency virus entry into T cells, Fc-fusion proteins have been intensely investigated for their effectiveness to curb a range of pathologies, with several notable recent successes coming to market. These promising outcomes have stimulated the development of novel approaches to improve their efficacy and safety, while also broadening their clinical remit to other uses such as vaccines and intravenous immunoglobulin therapy. This increased attention has also led to non-clinical applications of Fc-fusions, such as affinity reagents in microarray devices. Here we discuss recent results and more generally applicable strategies to improve Fc-fusion proteins for each application, with particular attention to the newer, less charted areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 2×
“…ability of IgG is consistent with the observation that decreased sialylation and galactosylation of IgG are observed in patients with arthritis (Jefferis, 2009), and modifications to the carbohydrate content of IgG have been posited as a molecular explanation for the ‘hygiene-hypothesis’…”
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Materials and methods for delivery of biological drugs
Zelikin, A. N., Ehrhardt, C., & Healy, A. M. (2016) · Nature Chemistry · doi:10.1038/nchem.2629 · Cited by 315
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Martinko, A. J., Truillet, C., Julien, O., Diaz, J. E., Horlbeck, M. A., Whiteley, G., Blonder, J., Weissman, J. S., Bandyopadhyay, S., Evans, M. J., et al. (2018) · eLife · doi:10.7554/elife.31098 · Cited by 91
Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y.-H. T., Rivera, J. M., Marcoulis, M., White, K. L., Whitman, J. D., Bapat, S. P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0242 · Cited by 72
Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
Self-citationBlundell, P. A., Lu, D., Dell, A., Haslam, S., & Pleass, R. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901145 · Cited by 29
“The aim of the current study was to reveal possible variation in functional glycosylation related to differences in two host cell lines, CHO-K1 and HEK 293-F, particularly as Abs and Fc fusions are the fastest growing therapeutic class in the pharmaceutical industry (34, 47, 48).”
BackgroundSelf-citationBlundell, P. A., Le, N. P. L., Allen, J., Watanabe, Y., & Pleass, R. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.795047 · Cited by 26
Self-citationBlundell, P. A., Lu, D., Wilkinson, M., Dell, A., Haslam, S., & Pleass, R. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801337 · Cited by 11
Self-citationEnforced Dimerization of CD45 by the Adenovirus E3/49K Protein Inhibits T Cell Receptor Signaling
Windheim, M., Reubold, T. F., Aichane, K., Gaestel, M., & Burgert, H.-G. (2023) · Journal of Virology · doi:10.1128/jvi.01898-22 · Cited by 11
Puranen, J., Koponen, S., Nieminen, T., Kanerva, I., Kokki, E., Toivanen, P., Urtti, A., Ylä-Herttuala, S., & Ruponen, M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109237 · Cited by 9
Metadata
- Authors
- Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J.
- Venue
- EMBO Molecular Medicine
- Published
- 2012-07-26
- Volume
- 4
- Issue
- 10
- Pages
- 1015-1028
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2141247392
- Cited by
- 476
- References
- 115
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.